- Home
- CABO vs MNPR Comparison
CABO vs MNPR Comparison
Compare CABO & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABO | MNPR |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.1M | 531.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CABO | MNPR |
|---|---|---|
| Price | $119.00 | $65.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $126.00 | $97.83 |
| AVG Volume (30 Days) | 135.3K | ★ 238.0K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,524,897,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $96.67 | $21.00 |
| 52 Week High | $384.11 | $105.00 |
Technical Indicators
Market Signals| Indicator | CABO | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 35.25 |
| Support Level | $114.86 | $64.25 |
| Resistance Level | $138.00 | $74.34 |
| Average True Range (ATR) | 6.07 | 4.44 |
| MACD | -0.78 | -0.58 |
| Stochastic Oscillator | 20.63 | 7.84 |
Price Performance
Historical ComparisonAbout CABO Cable One Inc.
Cable One Inc. is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. From a product standpoint, the majority of revenue comes from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols. Cable One Inc. owns its telecommunications infrastructure.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.